DelRicht Research Partners with Dr. Melita Tate of Grassroots Healthcare to Advance Long COVID Research in Tulsa

TULSA, OK –

Community-Based Partnership Targets Long COVID

Grassroots Healthcare, a community-based medical practice in Tulsa, Oklahoma, has partnered with DelRicht Research to conduct a clinical trial for long COVID. This collaboration is a significant step forward in the battle against COVID-19, particularly as research has shown that up to 30% of COVID-19 patients experience symptoms that can last for several months, if not longer.

Dr. Melita Tate, a practicing physician at Grassroots Healthcare, spoke about the importance of this partnership, stating, “As a community-based healthcare provider, we are committed to serving our patients and the local community. By partnering with DelRicht Research to conduct this long COVID trial, we can bring the latest medical research to our patients and provide them with the best possible care.”

Trial Objectives and Patient Inclusion

The long COVID trial will be conducted at Grassroots Healthcare and will involve patients who have experienced COVID-19 symptoms for more than 12 weeks. The trial will evaluate the efficacy and safety of a new treatment for long COVID, with the goal of identifying a treatment that can alleviate the symptoms of long COVID and improve patients’ quality of life.

Tyler Hastings, the Managing Partner at DelRicht Research, highlighted the significance of this collaboration, stating, “Partnering with Grassroots Healthcare to conduct this long COVID trial is an exciting opportunity to bring cutting-edge medical research to a local community. This trial has the potential to significantly improve the lives of patients who are experiencing long COVID symptoms and may provide a valuable treatment option for people around the world.”

“Partnering with Grassroots Healthcare to conduct this long COVID trial is an exciting opportunity to bring cutting-edge medical research to a local community. This trial has the potential to significantly improve the lives of patients who are experiencing long COVID symptoms and may provide a valuable treatment option for people around the world.”

— Tyler Hastings, Managing Partner at DelRicht Research

The long COVID trial will use a randomized, double-blind, placebo-controlled design, which is the gold standard for clinical research. Patients who meet the eligibility criteria will be enrolled in the trial and will receive either the investigational treatment or a placebo. The trial will be closely monitored to evaluate the efficacy and safety of the treatment and to ensure that all ethical guidelines and regulations are followed.

Dr. Tate emphasized the importance of patient safety and comfort throughout the trial, stating, “As a community-based medical practice, our patients are like family to us. We will do everything we can to ensure their safety and comfort during the trial, and we are committed to providing the best possible care to our patients.”

“As a community-based medical practice, our patients are like family to us. We will do everything we can to ensure their safety and comfort during the trial, and we are committed to providing the best possible care to our patients.”

— Dr. Melita Tate, Principal Investigator at DelRicht Research

Confronting Long COVID Through Continued Research

The long COVID trial is just one example of the important work being done to combat the long-term effects of COVID-19. As research continues to reveal more about the lasting impact of COVID-19, it is essential to develop treatments that can help patients recover and resume their normal lives.

Tyler Hastings expressed his optimism about the future of medical research, stating, “The collaboration between Grassroots Healthcare and DelRicht Research is an example of how the healthcare industry can come together to address complex medical issues. We are excited about the potential of this trial and are committed to continuing our efforts to advance medical research and improve patient outcomes.”

The partnership between Grassroots Healthcare and DelRicht Research is a testament to the power of collaboration in medical research. By bringing together the expertise and resources of these two organizations, the long COVID trial has the potential to make a significant impact on the lives of patients and to advance the field of medical research. As Dr. Tate stated, “We are proud to be a part of this groundbreaking trial, and we look forward to working with DelRicht Research to improve the health and well-being of our patients and our community.”